Seven more states to administer Covaxin from next week: Health Ministry

The inoculation drive was launched on January 16 with over three crore healthcare and frontline workers prioritized to get the jabs initially.

Published: 23rd January 2021 10:11 PM  |   Last Updated: 23rd January 2021 10:11 PM   |  A+A-

covaxin

For representational purpose. (Photo | Ashwin Prasath, EPS)

By PTI

NEW DELHI: Seven more states will be administering the indigenously-developed Covaxin from next week, the health ministry said on Saturday.

The Drugs Controller General of India (DCGI) had earlier this month approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.

Addressing a media briefing, Additional Secretary in the Union health ministry Manohar Agnani said that as on January 23, a total of 15,37,190 beneficiaries have been vaccinated for COVID-19 in 27,776 sessions.

The inoculation drive was launched on January 16 with over three crore healthcare and frontline workers prioritized to get the jabs initially.

In addition to the 12 states currently using Covaxin, seven new states -- Chhattisgarh, Gujarat, Jharkhand, Kerala, Madhya Pradesh, Punjab and West Bengal -- will be administering the vaccine from next week, Agnani said.

"The orientation of all programme managers of these seven states was conducted today by the ICMR (Indian Council of Medical Research) and the health ministry covering all aspects of implementation protocols," he said.

Giving updates on the ongoing COVID-19 vaccination drive, he said that "1,46,598 beneficiaries were vaccinated till 6 pm today and 123 adverse event following immunisation were reported till 6 pm on the eighth day of the vaccination drive."

No case of serious or severe adverse event following immunisation or death attributable to vaccination has been reported till date, the official said.

"Total six deaths have been reported so far (post-vaccination). In the last 24 hours, a person aged 56 years, a resident of Gurgaon, has died. The postmortem confirms that cardio-pulmonary disease was the reason for her death and it was not related to vaccination. None of these deaths have been causally linked with COVID-19 vaccination," he said.

Agnani said 11 hospitalisations post vaccinations have been reported till date.

"About 0.0007 per cent people have recorded hospitalisation against vaccinations. In the last 24 hours, one person has been hospitalised at a government hospital in Guntur in Andhra Pradesh who was vaccinated on January 20," he said.

Agnani said training of Immunization Programme Managers of 13 countries -- Bahrain, Bangladesh, Bhutan, Brazil, Maldives, Mauritius, Mongolia, Morocco, Myanmar, Nepal, Oman, Seychelles and Sri Lanka -- using Indian vaccines was conducted by the health ministry, covering all aspects of vaccine roll-out, over two days.

Of the 1,46,598 vaccinations carried out on Saturday, the highest number of people were inoculated in Gujarat (22,063) followed by Maharashtra (21,751), Odisha (14,892), Bihar (12,165) and Andhra Pradesh (11,562), according to ministry data.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.